Gética 2020

[ F I T C á n c e r - 6 ] 19 tients with muscle-invasive urothelial bladder carcino- ma (PURE-01): an open-label, single-arm, phase II study. Clin Oncol 2018:JCO1801148. [Epub ahead of print]. 18. Van der Heijden MS, van Dijk N, Smit L, et al. Pre-op- erative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO). Ann Oncol 2019;30(Suppl_5):v356-v402. 19. De Witt R, Kulkarni G, Uchio E, et al. Pembrolizum- ab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette- Guérin (BCG): phase 2 KEYNOTE-057 Trial. Ann Oncol 2018;29(Suppl_8):viii303-viii331. 20. FDA approves pembrolizumab for BCG-unrespon- sive, high-risk non-muscle invasive bladder cancer. Available from: https://www.fda.gov/drugs/resourc- es-information-approved-drugs/fda-approves-pem- brolizumab-bcg-unresponsive-high-risk-non-muscle-in- vasive-bladder-cancer. 21. Motzer RJ, Tykodi SS, Escudier B, et al. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with > 5 years of follow-up in patients with advanced renall cell carcinoma (aRCC). J Clin Oncol 2020;38(Suppl 6;abstr617). 22. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for ad- vanced renal cell carcinoma: extended follow-up of effica- cy and safety results from a randomized controlled, phase 3 trial. Lancet Oncol 2019;20(10):1370-85. 23. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcino- ma. N Engl J Med 2019;380(12):1103-15. 24. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcino- ma. N Engl J Med 2019;380(12):1116-27. 25. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T im- munotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411. 26. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastat- ic castration-resistant prostate cancer that had pro- gressed after docetaxel chemotherapy (CA184-083): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(7):700. 27. Beer TM, Known ED, Drake CG, et al. Randomized, dou- ble-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 2017;35:40. 28. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlates of anto-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443. 29. Fakhrejahani F, Madan RA, Dahut WL, et al. Avelum- ab in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2017;35(Suppl. 6S):abstract 159. 30. De Bono J, Goh JCH, Ojamaa K, et al. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory met- astatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2018;36(Suppl):abstr 5007. 31. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215. Logros y posicionamiento terapéutico de la inmunoterapia: tumores del aparato genitourinario